Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients with pulmonary arterial hypertension (PAH). All enrolled patients were being treated with a Phosphodiesterase-5 inhibitors (PDE-5 inhibitors), either as monotherapy or in combination with an endothelin receptor antagonist (ERA), and who did not reach their therapeutic goal. The study, which is a part of the collaboration between Bayer and Merck, is seeking to enroll patients at 26 sites in the United States with a total of 100 study sites worldwide.

July 5, 2017 — BioStable Science & Engineering Inc. announced the first commercial uses of the HAART 300 Aortic ...

Medtronic recently announced that its Reactive ATP therapy slows the progression of atrial fibrillation (AF) in patients with implanted cardiac devices. A robust, real-world analysis of nearly 8,800 patients was presented as a late breaking clinical trial at EHRA EUROPACE-CARDIOSTIM 2017, June 18-21 in Vienna, Austria.

June 30, 2017 — Pulsed cavitation ultrasound can be used to remotely soften human degenerative calcified biosprosthetic ...

Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the Impella 2.5 heart pump. The study analyzed patients with acute myocardial infarction complicated by cardiogenic shock (AMICS) undergoing a percutaneous coronary intervention (PCI) on an unprotected left main coronary artery (ULMCA). The study was published in the Journal of Interventional Cardiology.

Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for Xarelto (rivaroxaban) to include a 10 mg once-daily dose for reducing the risk of venous thromboembolism (VTE) after at least six months of standard anticoagulant therapy. This application is based on data from EINSTEIN CHOICE, which is the only study to find a non-vitamin K antagonist oral anticoagulant (NOAC), specifically two doses of Xarelto (10 mg and 20 mg), to be superior to aspirin in reducing the risk of recurrent VTE, with comparable rates of major bleeding.